Industries > Pharma > Global Graft versus Host Disease (GVHD) Market 2019-2029

Global Graft versus Host Disease (GVHD) Market 2019-2029

Acute, Chronic and Prophylaxis GVHD

PAGES: 162
PRODUCT CODE: PHA0384
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0384 Categories: , Tags: , , ,

The global graft versus host disease market is expected to grow at a CAGR of 7% from 2016-2021 and CAGR of 3% from 2019-2029. The market is expected to grow at a CAGR of 6% from 2016 to 2027. The market is estimated at $0.36bn in 2016, $0.51bn in 2021, and $0.64bn in 2026.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 162-page report you will receive 62 tables and 76 figures – all unavailable elsewhere.

The 162-page report provides clear detailed insight into the Graft versus Host Disease market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

• Revenue and growth forecasts to 2027 for the global GVHD market

• Revenue and growth forecasts to 2027 for the leading countries

• GVHD patient number forecast to 2027 per leading country, segmented into total allogenic cases, first allogenic cases, acute GVHD and chronic GVHD

• Revenue and growth forecasts to 2027 for the leading segments of the GVHD market by treatment type

• Revenue and growth forecasts to 2027 for the leading drugs in the GVHD market.

Global Graft versus Host Disease (GVHD) Market 2017-2027

Individual revenue forecasts to 2027 by treatment type:
• Prophylaxis GVHD
• Chronic GVHD
• Acute GVHD

Individual revenue forecasts to 2027 by product:

• Corticosteroids
– Methylprednisolone
– Budenofalk (effeverscent)

• ATG therapies
– Available ATG therapy (Thymoglobulin)
– Atege-Fresenius

• IL2Rα (CD25) inhibitors
– Simulect (Basiliximab)
– Leukotac (inolimomab)

• TNFα inhibitors
– Remicade (Infliximab)
– Enbrel (Etanercept)
– Co-stimulatory blockers
– Orencia (abatacept)
– Nulojix (belatacept)

• Other biologics
– Lemtrada (Alemtuzumab)
– Rituxan/MabThera (rituximab)
– Begedina (bt/9 anti-CD26)

• Calcineurin inhibitors
– Cyclosporine

• mTOR inhibitors
– Rapamune (sirolimus)
– Certican (everolimus)

• SOT therapies
– CellCept/Myfortic (mycophenolate mofetil)
– Prograf (tacrolimus)

• Anti-neoplastic therapies
– Velcade (bortezomib)
– Gleevec (imatinib)
– Methrotrexate
– Nipent (pentostatin)
– Cyclophosphamide

• Stem Cell Treatments
– In situ preparations of mesenchymal cells
– Prochymal (remestemcel-L)

• Extracorporeal Photophoresis
– Uvadex (Therakos)

Individual revenue forecasts to 2027 by country, further segmented by treatment type and by product:
• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

GVHD patient number forecasts to 2027 per leading country, segmented into:
• total allogenic cases
• first allogenic cases
• acute GVHD
• chronic GVHD

Visiongain’s study is intended for anyone requiring commercial analyses for the GVHD market. You find data, trends and predictions.

Buy our report today Global Graft versus Host Disease (GVHD) Market 2019-2029: Acute, Chronic and Prophylaxis GVHD.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Graft versus Host Disease (GVHD) Market 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Graft versus Host Disease (GVHD) Market 2019-2029


Latest Pharma news

Visiongain Publishes OTC Drugs & Dietary Supplements Market Report 2020-2030

The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.

23 September 2020

READ

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

READ

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

READ

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

READ

Categories

Category